| abstract |
Interferon (IFN), ribavirin (RBV), nucleoside inhibitor (NI), 2'C-methyladenosine (2'CMeA), sofosbuvir (SOF), or non-nucleoside inhibitor A or B (NNI-A or NNI-B Methods and compositions for efficiently and accurately determining the susceptibility of a hepatitis C virus (HCV) or HCV population to The method may comprise determining an HCV genotype or HCV phenotype associated with IFN, RBV, NI-1, 2 'CMeA, SOF, NNI-A, or NNI-B sensitivity. The method may further comprise selection of an appropriate treatment based on the determined genotype or phenotype. |